Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.

MLA

Garcia-Prieto, Carlos A., et al. “Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.” Journal of the National Cancer Institute, vol. 114, no. 3, Mar. 2022, pp. 436–45. EBSCOhost, https://doi.org/10.1093/jnci/djab194.

APA

Garcia-Prieto, C. A., Villanueva, L., Bueno-Costa, A., Davalos, V., González-Navarro, E. A., Juan, M., Urbano-Ispizua, Á., Delgado, J., Ortiz-Maldonado, V., Del Bufalo, F., Locatelli, F., Quintarelli, C., Sinibaldi, M., Soler, M., Castro de Moura, M., Ferrer, G., Urdinguio, R. G., Fernandez, A. F., Fraga, M. F., … Esteller, M. (2022). Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. Journal of the National Cancer Institute, 114(3), 436–445. https://doi.org/10.1093/jnci/djab194

Chicago

Garcia-Prieto, Carlos A, Lorea Villanueva, Alberto Bueno-Costa, Veronica Davalos, Europa Azucena González-Navarro, Manel Juan, Álvaro Urbano-Ispizua, et al. 2022. “Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.” Journal of the National Cancer Institute 114 (3): 436–45. doi:10.1093/jnci/djab194.